GB0111078D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0111078D0
GB0111078D0 GBGB0111078.2A GB0111078A GB0111078D0 GB 0111078 D0 GB0111078 D0 GB 0111078D0 GB 0111078 A GB0111078 A GB 0111078A GB 0111078 D0 GB0111078 D0 GB 0111078D0
Authority
GB
United Kingdom
Prior art keywords
treatment
combination
active compounds
pharmaceutically active
organic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0111078.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0111078.2A priority Critical patent/GB0111078D0/en
Publication of GB0111078D0 publication Critical patent/GB0111078D0/en
Priority to PT02738031T priority patent/PT1387836E/pt
Priority to CA002446051A priority patent/CA2446051A1/en
Priority to JP2002587426A priority patent/JP4365586B2/ja
Priority to DE60226225T priority patent/DE60226225T2/de
Priority to BR0209332-4A priority patent/BR0209332A/pt
Priority to AT02738031T priority patent/ATE393152T1/de
Priority to CNB028092937A priority patent/CN1314681C/zh
Priority to EP02738031A priority patent/EP1387836B1/en
Priority to ES02738031T priority patent/ES2301648T3/es
Priority to PCT/EP2002/004892 priority patent/WO2002090346A1/en
Priority to US10/475,419 priority patent/US7399761B2/en
Priority to US12/141,179 priority patent/US20090076003A1/en
Priority to US12/953,837 priority patent/US8034814B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0111078.2A 2001-05-04 2001-05-04 Organic compounds Ceased GB0111078D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0111078.2A GB0111078D0 (en) 2001-05-04 2001-05-04 Organic compounds
US10/475,419 US7399761B2 (en) 2001-05-04 2002-05-03 Phthalazine derivatives with angiogenesis inhibiting activity
AT02738031T ATE393152T1 (de) 2001-05-04 2002-05-03 Phtalazine derivate mit angiogenesis inhibierender wirkung
EP02738031A EP1387836B1 (en) 2001-05-04 2002-05-03 Phthalazine derivatives with angiogenesis inhibiting activity
JP2002587426A JP4365586B2 (ja) 2001-05-04 2002-05-03 血管形成阻害活性を有するフタラジン誘導体
DE60226225T DE60226225T2 (de) 2001-05-04 2002-05-03 Phtalazine derivate mit angiogenesis inhibierender wirkung
BR0209332-4A BR0209332A (pt) 2001-05-04 2002-05-03 Derivados de ftalazina com atividade inibidora da angiogênese
PT02738031T PT1387836E (pt) 2001-05-04 2002-05-03 Derivados de ftalazina com actividade de inibição de angiogénese
CNB028092937A CN1314681C (zh) 2001-05-04 2002-05-03 具有血管生成抑制活性的2,3－二氮杂萘衍生物
CA002446051A CA2446051A1 (en) 2001-05-04 2002-05-03 Phthalazine derivatives with angiogenesis inhibiting activity
ES02738031T ES2301648T3 (es) 2001-05-04 2002-05-03 Derivados de ftalazina con actividad inhibidora de la angiogenesis.
PCT/EP2002/004892 WO2002090346A1 (en) 2001-05-04 2002-05-03 Phthalazine derivatives with angiogenesis inhibiting activity
US12/141,179 US20090076003A1 (en) 2001-05-04 2008-06-18 Phthalazine Derivatives with Angiogenesis Inhibiting Activity
US12/953,837 US8034814B2 (en) 2001-05-04 2010-11-24 Phthalazine derivatives with angiogenesis inhibiting activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111078.2A GB0111078D0 (en) 2001-05-04 2001-05-04 Organic compounds

Publications (1)

Publication Number Publication Date
GB0111078D0 true GB0111078D0 (en) 2001-06-27

Family

ID=9914117

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0111078.2A Ceased GB0111078D0 (en) 2001-05-04 2001-05-04 Organic compounds

Country Status (12)

Country Link
US (3) US7399761B2 (https=)
EP (1) EP1387836B1 (https=)
JP (1) JP4365586B2 (https=)
CN (1) CN1314681C (https=)
AT (1) ATE393152T1 (https=)
BR (1) BR0209332A (https=)
CA (1) CA2446051A1 (https=)
DE (1) DE60226225T2 (https=)
ES (1) ES2301648T3 (https=)
GB (1) GB0111078D0 (https=)
PT (1) PT1387836E (https=)
WO (1) WO2002090346A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
WO2004002485A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1919906B1 (en) * 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
RU2522444C2 (ru) 2008-08-27 2014-07-10 Лео Фарма А/С Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物
JP2024505256A (ja) * 2021-01-28 2024-02-05 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (https=) 1957-05-07
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
JPH03106875A (ja) 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
DE69533057T2 (de) 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CN1660840A (zh) * 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis

Also Published As

Publication number Publication date
US8034814B2 (en) 2011-10-11
WO2002090346A1 (en) 2002-11-14
US20110130399A1 (en) 2011-06-02
ATE393152T1 (de) 2008-05-15
EP1387836A1 (en) 2004-02-11
ES2301648T3 (es) 2008-07-01
US7399761B2 (en) 2008-07-15
JP2004532241A (ja) 2004-10-21
DE60226225D1 (de) 2008-06-05
PT1387836E (pt) 2008-06-27
BR0209332A (pt) 2004-07-20
EP1387836B1 (en) 2008-04-23
DE60226225T2 (de) 2009-09-10
US20090076003A1 (en) 2009-03-19
CN1507444A (zh) 2004-06-23
US20040180899A1 (en) 2004-09-16
JP4365586B2 (ja) 2009-11-18
CN1314681C (zh) 2007-05-09
CA2446051A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
GB0222514D0 (en) Organic compounds
GB0211649D0 (en) Organic compounds
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
NZ514574A (en) Novel method of treatment
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
DE60038162D1 (de) Celecoxib in festkörperform mit erhöhter bioverfügbarkeit
DE60205455D1 (de) Naphthyridinderivate
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
PL2004653T3 (pl) 3-Podstawione N-(arylo- lub heteroarylo)-pirazo[1,5-a]pirymidyny jako inhibitory kinazy
GB0111078D0 (en) Organic compounds
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
ATE289805T1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
EP1027894A3 (en) Pharmaceutical preparation for the treatment of inflammatory processes
TH53088A (th) การใช้แซร์ดิวแทนท์ และเกลือซึ่งเป็นที่ยอมรับได้ในเชิงเภสัชกรรมของสารนี้สำหรับการเตรียมผลิตภัณฑ์ยาที่เป็นประโยชน์ในการรักษา หรือการป้องกันความผิดปกติทางอารมณ์ทั้งหมด ความผิดปกติทางการปรับตัว หรือความผิดปกติซึ่งผสม กันระหว่างความกังวล และความหดหู่

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)